



EXAMINER Laurie A. Mayes  
GROUP 1653  
APPLICANT Gordon W. Glazner  
SERIAL NO: ~~09/576,130~~  
FILED June 13, 2001  
FOR THERAPEUTIC USES FOR IP3 RECEPTOR-MEDIATED  
CALCIUM CHANNEL MODULATORS

Commissioner of Patents  
Washington, D.C., 20231  
U.S.A.

Dear Sir:

Responsive to the restriction/election requirement dated July 2,  
2003,

In the Claims:

Claims 1-31 are of record.

Claims 1-31 are subject to a restriction/election requirement.

Please amend the claims as follows:

Cancel claims 1-5.

6. (amended) A method of treating a human immunodeficiency virus  
(HIV) infection comprising:

administering an effective amount of a pharmaceutical composition  
comprising ~~an IP<sub>3</sub>-receptor-mediated calcium channel modulator~~ Xestospongine C  
(XeC) to an individual in need of said treatment.

Cancel claims 7-31.

32. (added) The method according to claim 6 wherein the XeC is